High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group.
OBJECTIVE
To determine whether intravenous immunoglobulin (IVIG) prevents severe infections during autologous bone marrow transplantation or equivalent high-dose myelosuppressive therapy.


METHODS
Randomized, stratified, nonblinded study.


METHODS
Three tertiary care university hospitals.


METHODS
One hundred seventy patients entered the study; 82 received IVIG and 88 were untreated controls. The study groups were similar for parameters capable of influencing the likelihood of infection.


METHODS
Intravenous immunoglobulin was given weekly at a dose of 500 mg/kg body weight from the initiation of cytotoxic therapy to the resolution of neutropenia.


METHODS
The development of bloodstream or other clinically proven infection, platelet use, and the development of alloimmunity to platelet transfusion.


RESULTS
Clinical infection, bacteremia, and fungemia occurred in 43%, 35%, and 6% of the IVIG-treated patients and in 44%, 34%, and 9% of the control patients. Gram-positive bacteremia and gram-negative bacteremia occurred in 28% and 11% of the IVIG group and in 23% and 13% of the control group. Death due to infection occurred in 4.9% of IVIG recipients and in 2.3% of controls. None of these observations was statistically significant (P > 0.2). Survival to hospital discharge was achieved in 86.6% of the IVIG group and in 96.6% of the control group. The survival difference (10%; 95% CI, 1.7% to 18.3%; P = 0.02) was due to a higher incidence of regimen-related toxic death in the IVIG-treated group.


CONCLUSIONS
The use of IVIG did not prevent infection. Fewer deaths occurred among controls due to a higher incidence of fatal hepatic veno-occlusive disease in patients receiving IVIG.
Wolff
S N
SN
Bone Marrow Transplant Program, Vanderbilt University, Nashville, TN 37232-4535.
Fay
J W
JW
Herzig
R H
RH
Greer
J P
JP
Dummer
S
S
Brown
R A
RA
Collins
R H
RH
Stevens
D A
DA
Herzig
G P
GP
D000293:Adolescent; D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000517:prevention & control; D001855:Bone Marrow Diseases / Q000209:etiology / Q000276:immunology*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D016469:Fungemia / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy; D009503:Neutropenia / Q000276:immunology; D009894:Opportunistic Infections / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous
D016756:Immunoglobulins, Intravenous